CereVasc, Inc. Announces Publication of a Multi-Center Study Evaluating the eShunt® System in the Treatment of Patients with NPH

95% of Participants Demonstrated Clinical Improvement with No Device-Related Serious Adverse Events Through 90-Day Follow-Up

Excerpt from the Press Release:

BOSTON, Feb. 24, 2026 /PRNewswire/ — CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, today announced results from a prospective, multi-center, single-arm clinical study evaluating the safety and clinical outcomes of the eShunt System in patients with normal pressure hydrocephalus (NPH). The results were published in the Journal of NeuroInterventional Surgery (JNIS).

66 patients were treated in the study at 12 sites in the United States and Argentina. Key results through 90-day follow-up include:

• 0% rate of device-related serious adverse events (SAEs)
• 3.0% rate of procedure-related SAEs, all resolved without surgical intervention
• 95% of participants demonstrated improvement in at least one of the three primary clinical symptoms of NPH (gait disturbance, cognitive impairment, and urinary incontinence)
• Statistically significant improvement from baseline was documented in all three primary clinical symptoms of NPH
• Zero observations of symptomatic or radiologic cerebral hemorrhage or over-drainage, confirmed by blinded, independent core lab MR and CT image analysis
• Zero instances of infection related to the procedure or device

“The outcomes achieved in this study are highly encouraging. The favorable safety profile, along with statistically significant symptom improvements observed at the 90-day follow-up, provides an early clinical signal that supports continued evaluation of an endovascular approach for the treatment of NPH,” said Charles Matouk, MD, Vice Chair of Clinical Affairs, Neurosurgery and Chief, Neurovascular Surgery at Yale School of Medicine.

Click the button below to read the entire Press Release:

Continue Reading The Press Release